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Purpose: Pubertal suppression is standard of care for early pubertal transgender youth to prevent the
development of undesired and distressing secondary sex characteristics incongruent with gender identity.
Preliminary evidence suggests pubertal suppression improves mental health functioning. Given the widespread
changes in brain and cognition that occur during puberty, a critical question is whether this treatment impacts
neurodevelopment.
Methods: A Delphi consensus procedure engaged 24 international experts in neurodevelopment, gender de-
velopment, puberty/adolescence, neuroendocrinology, and statistics/psychometrics to identify priority research
methodologies to address the empirical question: is pubertal suppression treatment associated with real-world
neurocognitive sequelae? Recommended study approaches reaching 80% consensus were included in the
consensus parameter.
Results: The Delphi procedure identified 160 initial expert recommendations, 44 of which ultimately achieved
consensus. Consensus study design elements include the following: a minimum of three measurement time
points, pubertal staging at baseline, statistical modeling of sex in analyses, use of analytic approaches that ac-
count for heterogeneity, and use of multiple comparison groups to minimize the limitations of any one
group. Consensus study comparison groups include untreated transgender youth matched on pubertal stage,
cisgender (i.e., gender congruent) youth matched on pubertal stage, and an independent sample from a
large-scale youth development database. The consensus domains for assessment includes: mental health, exec-
utive function/cognitive control, and social awareness/functioning.
Conclusion: An international interdisciplinary team of experts achieved consensus around primary methods
and domains for assessing neurodevelopmental effects (i.e., benefits and/or difficulties) of pubertal suppression
treatment in transgender youth.
Keywords: expert consensus; Delphi; puberty blockers; GnRHa; transgender; adolescents
Introduction
Standards of care established by the World Professional
Association for Transgender Health1 and the Endo-
crine Society2 recommend pubertal suppression for
gender dysphoric transgender youth during early pu-
berty (i.e., Tanner stages 2–3).3,4 Pubertal suppression
is achieved through administration of gonadotropin-
releasing hormone agonists (GnRHa). When adminis-
tered in early puberty, GnRHa suppress endogenous
sex hormone production and prevent the development
of undesired and irreversible secondary sex characteris-
tics, thereby minimizing distress associated with puber-
tal development incongruent with gender identity.5 For
youth who later decide to initiate estrogen/testosterone
(gender-affirming hormones [GAH]) treatment to in-
duce development of the desired secondary sex charac-
teristics, pubertal suppression may minimize the need
for more invasive, surgical interventions (e.g., facial
and chest surgery). For youth who decide not to pursue
GAH treatment, discontinuing GnRHa will reactivate
the hypothalamic-pituitary-gonadal axis and endoge-
nous puberty will resume.6
Three longitudinal studies have examined psychoso-
cial outcomes in GnRHa-treated transgender youth;
two (conducted by the same research group) followed
a single cohort over time, immediately before initiat-
ing GAH (N = 70)7 and later in early adulthood after
surgery for gender affirmation (N = 55).8 The third
study compared groups of GnRHa-treated (n = 35)
and untreated (n = 36) youth longitudinally.9 Findings
across these studies include significant reductions in
depressive symptoms and improvement in overall psy-
chosocial functioning in GnRHa-treated transgender
youth. A fourth cross-sectional study compared ado-
lescents diagnosed with gender dysphoria (GD), who
were treated with GnRHa and close to starting GAH
treatment (n = 178), adolescents newly referred for GD
evaluation (n = 272), and cisgender adolescents recrui-
ted from the general population (n = 651) on self-
reported internalizing/externalizing problems, self-harm/
suicidality, and peer relationships.10 Before medical
treatment, clinic-referred adolescents reported more
internalizing problems and self-harm/suicidality and
poorer peer relationships compared to age-equivalent
peers. GnRHa-treated transgender adolescents had
fewer emotional and behavioral problems than clinic-
referred, untreated adolescents and had compara-
ble or better psychosocial functioning than same-age
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cisgender peers. In addition to studies of youth, the
2015 U.S. Transgender Survey included questions
about past gender-affirming medical treatment, includ-
ing pubertal suppression. These questions were asked
retrospectively and linked to reported current and life-
time mental health.11 Individuals who received puber-
tal suppression treatment (n = 89), when compared to
those who wanted pubertal suppression, but did not
receive it (n = 3405), had lower odds of endorsing life-
time suicidal ideation on the survey. Given these five
studies and the presumed reversibility of GnRHa treat-
ment, pubertal suppression is increasingly offered to
early pubertal transgender youth. It is important to
note that there has been only one longitudinal report
of adult outcomes,8 and questions remain regarding
the potential for both positive and disruptive effects
of pubertal suppression on neurodevelopment.12–14
The pubertal and adolescent period is associated
with profound neurodevelopment, including trajecto-
ries of increasing capacities for abstraction and logical
thinking,15 integrative thinking (e.g., consideration of
multiple perspectives),16,17 and social thinking and
competence.18,19 During this period, there is a develop-
mental shift toward greater exploration and novelty
seeking,20,21 salience of peer perspectives and interac-
tions,22 and accelerated development of passions/
interests and identities.23 These developments lay the
groundwork for adult functioning.18,24 At the level of
the brain, several primary neurodevelopmental pro-
cesses unfold during adolescence, including myelin
development25 and changes in neural connectivity26;
synaptic pruning27 and gray matter maturation28,29;
changes in functional connectivity30; and maturation
of the prefrontal cortex31 and the ‘‘social brain’’ net-
work.19 Adolescent neurodevelopmental processes un-
derlie mental health risks, resilience, and outcomes.32,33
Considerable research has addressed the effects of
puberty-related hormones on neurodevelopment, in-
cluding hormone manipulation studies in nonhuman
animals and observational studies in humans. Animal
studies demonstrate pubertal hormones exert broad
neuronal influence, including effects on neurogenesis,
differentiation, apoptosis, dendritic branching, spine
density, and regional gray and white matter volumes.30,34
Androgen and estrogen receptors are found in high
density within the hypothalamus and amygdala, and
are also present in the hippocampus, midbrain, cere-
bellum, and cerebral cortex of the rodent and
monkey.35–37 This widespread receptor distribution in
rodents may explain the diverse effects of pubertal hor-
mones on both reproductive and nonreproductive
behaviors, including anxiety, scent-marking, and food
guarding.34 In human studies, pubertal progression has
been linked to developmental changes in reward,38
social,39 and emotional processing40 as well as cognitive/
emotional control.41 However, consensus regarding
pubertal impacts at the neural level—such as puberty-
associated changes observed in magnetic resonance
imaging (MRI) measures—has been more difficult to
achieve.42 Distinct puberty-related neurodevelopmen-
tal trajectories have been differentiated by sex.43
The combination of animal neurobehavioral re-
search and human behavior studies supports the no-
tion that puberty may be a sensitive period for brain
organization:44–46 that is, a limited phase when devel-
oping neural connections are uniquely shaped by
hormonal and experiential factors, with potentially life-
long consequences for cognitive and emotional health.
Studies have linked early life adversity to early pu-
berty onset47 and early puberty onset to poorer mental
health.48 There is also some evidence to suggest that
delayed puberty onset predicts slightly poorer adult
functional outcomes.49 Taken as a whole, the existing
knowledge about puberty and the brain raises the pos-
sibility that suppressing sex hormone production
during this period could alter neurodevelopment in
complex ways—not all of which may be beneficial.
Two small studies have assessed impacts of pubertal
suppression on neural and cognitive functioning in
peripubertal transgender youth. Staphorsius et al.
compared brain and behavioral responses of GnRHa-
treated (8 transgender girls [birth-assigned male] and
12 transgender boys [birth-assigned female]) and un-
treated transgender youth (10 of each sex) during an
executive function task.50 No group differences were
found in task load-related brain activation; GnRHa-
treated transgender girls demonstrated poorer perfor-
mance compared with untreated transgender boys
and cisgender controls. Schneider et al. evaluated a
single pubertal transgender girl undergoing GnRHa
with MRI scans of white matter and cognitive assess-
ments at baseline (before GnRHa initiation) and at
22 and 28 months of pubertal suppression treat-
ment.51 During follow-up, white matter fractional an-
isotropy (i.e., a measure of axonal diameter, fiber
coherence, and myelination) did not increase in the
manner otherwise expected during puberty. By 22
months of pubertal suppression treatment, working
memory scores dropped by more than half a standard
deviation.
248 CHEN ET AL.
Larger-scale, longitudinal studies are required to
understand possible neurodevelopmental impacts of
pubertal suppression over time in transgender youth.
Suppressing puberty may reduce dysphoria and dimin-
ish risks for poor mental health in this population,
thereby exerting neuroprotective effects. If pubertal
suppression disrupts aspects of neurodevelopment, it
is possible these effects are temporary, with youth
‘‘catching up’’ developmentally after transitioning to
GAH treatment or discontinuing GnRHa. However,
pubertal suppression may prevent key aspects of devel-
opment during a sensitive period of brain organization.
Neurodevelopmental impacts might emerge over time,
akin to the ‘‘late effects’’ cognitive findings associated
with certain oncology treatments.52 In sum, GnRHa
treatment might produce a myriad of varied impacts,
both positive and disruptive.
The goal of this study was to develop a framework in
which these questions could be asked, and ultimately
answered. We identify priority research methodologies
that can be used to address the empirical question of
how pubertal suppression in transgender youth may
affect neurodevelopment and real-world functioning.
Given the complexity of neural development during
the pubertal period and the novelty of developmental
research with transgender youth, this study employed
a Delphi consensus method to leverage international
expertise in neurodevelopment, gender development,
puberty/adolescence, neuroendocrinology, and statistics/
psychometrics. By engaging a community of experts in
an iterative consensus-building procedure, this study
aimed to advance thinking about efficacious designs
by moving beyond individual research efforts and
single-discipline approaches.
Methods
The Delphi procedure is a reliable iterative research
method for establishing expert agreement,53,54 and
has been used extensively to address health-related
questions, particularly in emerging fields of clinical
care.55–57 In the first round of a two-round Delphi
procedure, a key question is presented to experts,
who remain anonymous to one another throughout
the Delphi process. Each expert provides responses/
solutions to the question, which are then combined
and organized by the study team. In the Delphi
round two, experts rate each proposed statement/
solution according to the level of agreement. Responses
reaching the a priori consensus criterion are included
as consensus statements. Given its anonymous iterative
nature, the Delphi method avoids problems of typical
expert work groups (e.g., adhering to the perspectives
of more senior workgroup experts, inflexibly defending
ideas) and allows for interaction among larger groups
of experts from diverse locations and disciplines
through asynchronous communication.58–60
We employed a two-round Delphi procedure to
obtain expert consensus regarding the most efficacious
research design elements to address the following re-
search question: What, if any, real-world impact does
pubertal suppression have on transgender children’s
cognitive and neural development? International ex-
perts in relevant research fields were identified and
invited as follows:
1. An independent advisory panel consisting of five
experts across key disciplines (see Acknowledg-
ments section) was formed to identify interna-
tional experts who, based on knowledge and
experience, could best propose a research design
to assess neurodevelopmental impacts of pubertal
suppression in transgender youth.
2. Thirty-two recommended experts were vetted
for their expertise; all met required criteria (i.e.,
a minimum of 10 first-author publications in rel-
evant fields).
3. These experts were invited to participate in the
Delphi procedure and were informed they
would be invited to consider being a co-author
of the resulting article. Twenty-eight experts
responded: 20 agreed to participate, 4 declined
due to lack of time, and 4 declined due to self-
reported lack of expertise in this research area.
Snowball sampling identified an additional 16
recommended experts, who were vetted (as de-
scribed above) for their experience. Eight met
criteria and were invited. Five of these experts
participated, yielding a total of 25 experts agree-
ing to participate, 24 of whom completed the
Delphi process. See Table 1 for academic institu-
tion locations and areas of expertise represented
in the expert panel.
The Ann & Robert H. Lurie Children’s Hospital of
Chicago Institutional Review Board found that an ex-
pert Delphi consensus initiative did not require in-
formed consent since the experts were direct partners
in the research product. The first round of Delphi
survey was distributed through the REDCap online
survey platform and presented an overview of the
research question with the following prompt for
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respondents: ‘‘What methods and tools should we use
to identify clinically meaningful neurodevelopmental
impacts of pubertal suppression? What type of longitu-
dinal design and follow-ups are both practical and
appropriate? What comparison groups might we con-
sider?’’ This initial process yielded 131 distinct re-
search design considerations; multiple descriptions of
the same concept were collapsed into single statements.
In the second Delphi round, each first-round research
design consideration was presented back to the ex-
perts and rated as follows: a priority idea/approach or
not a priority idea/approach. Experts could also select,
‘‘cannot rate due to lack of expertise.’’ The first Delphi
round also yielded lists of potential comparison groups
and assessment domains (29 items). In the second Del-
phi round, participants were asked to rank order these
items according to priority. For the priority rankings of
comparison groups, the top-rated comparison group by
each expert was given a value of 2 and the second rated
comparison group was given a value of 1. A mean was
calculated for each comparison group option based on
these values and these mean scores were used to identify
the overall priority rankings. For the list of priority do-
mains to measure, a parallel approach was taken with
the top 6 domains ranked by each expert.
All experts participated in the second Delphi round.
Twenty-two of the Delphi experts participated in the
construction of the resulting article and are co-authors
listed in reverse alphabetical order by last name (au-
thors 5–26). The Results section contains the exact
statements endorsed as a ‘‘priority’’ approach by 80%
or more of the Delphi panel.
Results
Four of the 131 individually presented statements were
excluded from analyses because fewer than 15 experts
rated them. Of the remaining 127 statements, 44 met
the 80% or higher criterion for consensus and inclusion
(see Table 2 for endorsement rates by statement). The
average endorsement rate of included statements was
89.4%.
Consensus parameter
Study design considerations. A multicenter design
with more than a single clinic will be necessary to re-
cruit a sufficient sample size, as the effect size will likely
be small. Meaningful effect sizes must be determined to
ensure sufficient recruitment to power multiple expec-
ted comparisons accounting for attrition in a longitudi-
nal design. Three time points of measurement are the
absolute minimum. It will be necessary to manage
the effects of repeated testing with a particular focus
on minimizing the practice effects of a longitudinal de-
sign with multiple time points. For cognitive assess-
ments, standardized batteries should be employed as:
(1) there may be a larger database of norms available
that the cohort could be compared to, in addition to a
local comparison (control) group(s), (2) general compos-
ite scores within test batteries tend to provide more reli-
able and stable scores than individual tests, and (3) tasks
within a category may be swapped in case of worries for
learning effects. In any study of cognitive change based
on serial assessments, reliability of measures is para-
mount (the consensus in the field is that tests should
have a minimum test-retest reliability of > 0.70). It
may be pragmatic to use measures and methods from
large representative studies, such as the Adolescent
Brain Cognitive Development (ABCD) Study.
All processes being studied (e.g., gender identity,
mental health, neural structure, and function) display
considerable heterogeneity, and methods that fail to
capture this will provide distorted findings and lead
to biased clinical recommendations. Analyses based
on group means (e.g., regression or ANOVAs) are un-
likely to generalize to all individuals being treated.
Therefore, it is necessary to collect enough data per
person to characterize individual trajectories of change
over time.
Table 1. Institutional Representation and Self-Reported
Areas of Expertise
n















Expert in GnRHa 2
Other (write in) 4
Developmental social neuroscience 1
Transgender health 1
Genetics of sex chromosomes 1
Gender development 1
aExperts endorsed as many areas of expertise as applicable.
GnRHa, gonadotropin-releasing hormone agonists.
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Table 2. Consensus Priority Recommendations Ordered by Consensus Ratings Within Categories
Study design considerations
1 It would be helpful to follow these youth through and beyond initiation of cross-sex hormone treatment. Some aspects of
human adolescent brain development are more related to pubertal hormone status than age per se, and to the extent
that pubertal suppression may also put some features of brain development on hold; it would be good to know whether
these features ‘‘catch up’’ once cross-sex hormone treatment has begun or whether a sensitive window for hormone-
dependent brain development has closed.
22/22
2 Follow cohort after GnRHa treatment ends—collect data after the youth transition to GAH (when they complete their
GnRHa treatment).
22/23
3 Any neurocognitive effect of GnRHa pubertal suppression may be complicated by the psychosocial and affective aspects of
the transgender experience. This means that you would have to include multivariate models of both cognitive and
psychosocial functioning.
22/23
4 Need to determine meaningful effect sizes and ensure sufficient statistical power for multiple expected comparisons with
attrition.
21/22
5 Across the course of the study, three assessment points is the absolute minimum. 20/21
6 Need to use a multicenter design (not just one clinic). 21/23
7 Effects of GnRHa may not appear for several years. Any difference in brain structure due to GnRHa is likely to be seen over
time (long term), rather than immediately.
20/22
8 Social and affective learning process may be affected by pausing puberty. These social and affective learning processes
might cause subtle short-term differences that could ultimately cause clinically impactful and meaningful longer-term
effects.
17/19
9 Of particular interest would be to also monitor the impact of hormonal therapy. One could then ask, ‘‘Does the trajectory
change in response to cross-sex hormonal therapy or do they stay on the same trajectory as when they were on GnRHa?’’
16/18
10 Assess target and comparison groups before puberty. 20/23
11 Need to manage the effects of repeated testing (i.e., minimize the practice effect of a longitudinal design with multiple
time points).
19/22
12 The effect size will likely be small—therefore, you would need a large sample size. 19/23
13 The research design will need to account for the differences between youth who are assumed male versus assumed female
as biological sex is differentially related to rate and pattern of cognitive development, connectome distinctiveness, and
timing of peak brain volume.
19/23
14 All processes being studied (e.g., gender identity, mental health, and neural structure and function) display huge amounts
of heterogeneity, and research methods that fail to capture this will provide distorted findings and lead to biased clinical
recommendations. Analyses based on mean levels of these processes are unlikely to generalize to all individuals being
treated (e.g., regressions or ANOVAs that compare groups with a slew of covariates). It is, therefore, necessary that
enough data are collected per person to capture personalized trajectories of change across time. And the data need to
be modeled in ways that reflect the heterogeneity of individual characteristics and trajectories.
18/22
Comparison groups and recruitment
15 At least one control group should be cisgender participants as this area of research (i.e., hormones and the adolescent
brain) is still rather new and more data are needed on all youth during this stage.
20/22
16 Critical to match the groups carefully to allow for evaluation of the effects of repeated testing (practice effects). 20/22
17 Comparison groups should be matched for pubertal stage. 19/21
18 Recruit all gender dysphoric youth across the pubertal age range, including those who are treated with GnRHa and those
who are not.
18/21
19 This is not dissimilar from issues of discerning differences in cognitive trajectories in normal aging versus
neurodegenerative disorders. The basic question involves cognitive growth curves among cisgender and transgender
children overtime. There have been large-scale large-sample studies that have produced trajectories of brain
development during the pre-pubertal, pubertal, and adolescent periods that could treated like a ‘‘brain growth curve.’’
15/18




21 Measure gonadal hormone levels. 23/23
22 Collect information on menstrual cycle and contraceptive use for female adolescents involved in the study. 23/23
23 Measure Tanner staging (i.e., secondary sex characteristics). 21/23
24 Measure height/weight. 18/22
Domains to measure
25 Use white matter microstructure scans (diffusion tensor imaging)—and use a longitudinal imaging pipeline (which exists)
for processing these data with scientific rigor.
15/15
26 A pragmatic methodological implication is to consider: (1) not only relying solely on measures of performance and
behavior but also measures of learning and motivation, and (2) not only relying solely on measures of cognitive
capacities but also on social, affective, and value-based learning processes.
19/20
27 If MRI is included, consider imaging approaches focused on the following domains: social-emotional processing, executive
functioning, risk and reward processing, and self-concept.
20/22
28 Studies in laboratory rodents show that testosterone, acting during puberty, programs the ability to adapt behavior as a
function of social experience—therefore, include instruments that evaluate social proficiency.
19/21
29 Use diffusion tensor imaging to analyze white matter at the microstructural level. 17/19
(continued)
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Any GnRHa-induced neurocognitive effect may be
complicated by psychosocial and affective aspects of
the transgender experience. Therefore, multivariate
models of both cognitive and psychosocial functioning
should be included. Accounting for differences be-
tween birth-assigned male youth versus birth-assigned
female youth is important, as sex is differentially re-
lated to the rate and pattern of cognitive development,
connectome distinctiveness, and timing of peak brain
volume. Assessments should begin before puberty in
both treatment and comparison groups. The effects
of pubertal suppression may not appear for several
years. Any GnRHa-related difference in brain structure
is likely to be observed over the long term, rather than
immediately. Shifts in social and affective learning pro-
cesses might cause subtle short-term differences that
could ultimately result in clinically impactful longer-
term effects. Therefore, studies should follow GnRHa-
treated youth over time, including the time period
after GnRHa treatment ends and/or when GAH com-
mence. Some aspects of human adolescent brain devel-
opment are more related to pubertal hormone status
than age per se. To the extent that pubertal suppression
may also put some features of brain development on
hold, it is critical to know whether these features
‘‘catch up’’ (either once GAH treatment is initiated or
if the adolescent elects to stop GnRHa and resume en-
dogenous puberty), or whether a sensitive window for
hormone-dependent brain development has closed.
One way to measure this is to assess whether neurode-
velopment shifts in response to initiating GAH follow-
ing pubertal suppression: Do GnRHa-treated youth stay
on the same neurodevelopmental trajectory as when
puberty was suspended or does this trajectory change?
Comparison groups. To assess neurodevelopmental
trajectories associated with GnRHa treatment, more
than one comparison group is needed to minimize
the limitations of any one comparison group. No single
comparison group is ideal for this study question.
Table 2. (Continued)
Study design considerations
30 Studies in laboratory rodents show that ovarian hormones, acting during puberty, program cognitive flexibility by exerting
long-lasting effects on excitatory-inhibitory balance in prefrontal cortex—so include instruments that evaluate
behavioral flexibility.
18/21
31 Examine white matter development, which is important for processing speed. 17/20
32 Important to measure emotional functioning because it is bidirectionally related to executive functioning. 16/19
33 Look at white matter characteristics since they seem to develop during puberty under the influence of sex hormones. 15/18
34 One cannot study everything or study everything well. It will be critical to identify the priorities in such a study, as there is a
danger of doing too much here. Consider the outcomes that matter most and the hypothesized mediating mechanisms.
Focus on the outcomes of interest.
19/23
35 There is no clear evidence that progressing through puberty later than peers is associated with delayed maturation of
abstract reasoning, executive function, and social capacities.
18/22
36 Use structural MRI (T1/T2)—and use a longitudinal imaging pipeline (which exists)—for processing these data with
scientific rigor.
13/16
37 There is an emerging shift in thinking about the increase in reward sensitivity and sensation-seeking during puberty as
related to social value learning. Dopamine release is not primarily a ‘‘reward’’ signal, but rather a learning signal (e.g.,
prediction error signal)—the natural increased salience of social learning (status, prestige, being admired, respected,
liked, etc.) These pubertal changes may have small effects on immediate behavior, yet that could contribute to changes
in patterns of behavior over time, which could lead to large individual differences in developmental trajectories for
people, such as if they had blocked puberty.
13/16
Measurement approaches
38 In any study of cognitive change based on serial assessments, reliability of the measure is paramount. The consensus in the
field is that tests should have a minimum test-retest reliability of > 0.70.
20/20
39 Behavioral measurements should include standardized measures appropriate for repeated assessment with high test-retest
reliability.
21/22
40 Match acquisition parameters between imaging sites. 17/18
41 Consider implementing measures and methods from large representative protocols, such as the ABCD. 17/18
42 Neuroimaging should parallel the behavioral study—neural measures should be linked to neurocognitive and behavioral
measures.
19/22
43 For cognitive assessment, use a standardized battery for two reasons: (1) there might be a larger database of norms
available that the cohort could be compared to, in addition to the likely to be small comparison (‘‘control’’) group, and (2)
tasks within a category may be swapped in case of worries for learning effects.
18/21
44 Use ‘‘test batteries’’ that provide a general composite score as well as specific composites. By virtue of being composites,
scores tend to be more reliable and stable than individual test scores.
17/20
The proportion represents the number of experts endorsing an item as a ‘‘priority’’ out of the total number of experts who rated the item as
‘‘priority’’ or ‘‘not priority.’’ The denominator represents the number of experts rating an item as a ‘‘priority’’ or ‘‘not priority’’ (as opposed to ‘‘cannot
rate due to lack of expertise’’ or skipping the item).
ABCD, Adolescent Brain Cognitive Development Study; GAH, gender-affirming hormones; MRI, magnetic resonance imaging.
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A rank order of possible comparison groups is pro-
vided in Table 3. Groups should also be well matched,
given the effects of a repeated testing design (e.g., prac-
tice effects). Matching for pubertal/developmental
stage will be critical, including Tanner staging, gonadal
hormone levels, height and weight, and, among youth
assigned female at birth, menstrual cycle and contra-
ceptive use. A primary comparison should be between
GnRHa-treated transgender youth and untreated
transgender youth, but it will also be important to in-
clude comparisons with cisgender samples as research
on hormones and the adolescent brain is still novel
and emerging and more data are needed on all youth
during this developmental period. One way to accom-
plish the latter is to employ existing large-scale data-
bases from studies of brain development during the
pre-pubertal, pubertal, and later-adolescent periods,
treating them as brain growth curves for comparisons.
This approach is similar to the differentiation of cogni-
tive trajectories in normal aging versus neurodegener-
ative disorders. The basic research question involves
comparing cognitive growth curves over time.
Domains to assess. It will be critical to prioritize as-
sessment domains based on hypothesized mediating
mechanisms, with the most important domains to
measure as follows: mental/behavioral health, puber-
tal stage, executive function/control, gender identity/
dysphoria, and social awareness/functioning. See Table 4
for a complete list of ranked domains. Although we
(the Delphi experts) identify executive function/control
and social functioning as key domains to measure, it is
important to note that there is no clear evidence that
progressing through puberty later than peers is associ-
ated with delayed maturation of abstract reasoning, ex-
ecutive function, and social capacities. Executive function
and emotional functioning are bidirectionally related,
and for this reason, the two should be integrated in mod-
els/analyses. In addition, cognitive/behavioral flexibil-
ity, a component of executive functioning, should be
measured, given that studies in rodents show ovarian
hormones, acting during puberty, program cogni-
tive flexibility by exerting long-lasting effects on
excitatory-inhibitory balance in the prefrontal cor-
tex.61 Studies in rodents also demonstrate that testos-
terone, acting during puberty, programs the ability to
adapt behavior as a function of social experience.34
Measurement approaches should extend beyond cogni-
tive capacities alone, embedding social, affective, and
value-based learning processes. There is an emerging
shift in thinking about increases in reward sensitivity
Table 3. Rank Order of Priority Comparison Groups
Rank order
of priority Comparison group
1 Transgender youth who do not take GnRHa matched on
pubertal status at the beginning of the study
2 Cisgender typically developing adolescents matched on
pubertal status at the beginning of the study
3 Use a standardized battery and/or a large existing
database of norms to compare to (in addition to a
smaller comparison group)
4 Transgender youth who commence GnRHa treatment
earlier compared to later in puberty
5 Siblings of transgender youth enrolling in the study
(to serve as genetic and shared environmental
controls)
6 Mixed clinical group of adolescents presenting for MH
assessment/treatment in an outpatient setting
matched on pubertal status
7a Peers with mood disorders (to control for the
overoccurrence of mental health distress in
transgender youth) matched on pubertal status
7a Youth with precocious puberty who are given GnRHa to
delay puberty
This priority sequence was based on participants’ top 2 ranked com-
parison groups, where the top rated comparison group was given a
value of 2 and the second rated comparison group was given a value
of 1. A mean score was derived for each comparison group based on par-
ticipants’ ratings and ordered from highest to lowest.
aComparison groups received the same mean score in the ranking.
Table 4. Rank Order of Priority Domains of Characterization
and Assessment
Rank order
of priority Domains of characterization and assessment
1 Mental/behavioral health (including suicidality/
hopelessness)
2 Pubertal stage/development (Tanner staging/
hormone levels)
3 Executive function/control and attention
4 Gender identity/dysphoria
5 Social awareness/functioning




10 Physical health symptoms and outcomes (especially
in adulthood)
11 Adaptive/independence skills
12 General cognitive functioning (IQ)
13 Sensation seeking, risk taking, reward sensitivity,
and motivation





This priority sequence was based on participants’ top 6 ranked do-
mains to measure, where the top rated domain was given a value of 6
and the second rated comparison group was given a value of 5, and
so on. A mean score was derived for each domain based on participants’
ratings and ordered from highest to lowest.
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and sensation-seeking during puberty as related to
social-value learning.18 Dopamine release is not primar-
ily a ‘‘reward’’ signal, but rather a learning signal (e.g.,
prediction error signal)—the natural increased salience
of social learning (e.g., status and prestige, being ad-
mired, respected, and liked). The effects of suspending
puberty on the salience of social-value learning might
produce small near-term effects, but could contribute
to changes in patterns of behavior over time, leading to
large individual differences in developmental trajectories
for GnRHa-treated youth.
If neuroimaging is included, imaging approaches
should focus on the following domains: social/
emotional processing, executive functioning, risk and
reward processing, and self-concept. Neuroimaging
should parallel behavioral assessment. Neural measures
should be linked to neurocognitive and behavioral
measures. Acquisition parameters should be matched
between imaging sites. Investigation of white matter
development is important as myelination progresses
during puberty, likely under the influence of sex hor-
mones,62 and is related to cognitive processing speed.
Both structural MRI and diffusion tensor imaging ap-
proaches should be used for white matter imaging
and analyzed using a longitudinal imaging pipeline
for processing these data with scientific rigor.
Discussion
Puberty suppression has become an increasingly
available option for transgender youth, and its bene-
fits have been noted, particularly in the area of mental
health. However, puberty is a major developmental
process and the full consequences (both beneficial
and adverse) of suppressing endogenous puberty are
not yet understood. The experts who participated in
this procedure believe the effects of pubertal suppres-
sion warrant further study, and this Delphi consensus
process develops a framework from which future re-
search endeavors can be built.
Expert consensus emphasized a minimum of three
measurement time points, inclusion of multiple com-
parison groups to minimize the limitations of any
one group, precision pubertal staging at baseline, ac-
counting for sex in design and analysis, and the use
of designs that capture heterogeneity in processes
being studied. Focus on longer-term trajectories and
outcomes was emphasized, given that effects of pu-
bertal suppression on various processes may not be ev-
ident in the near term, and responses to delayed receipt
of gonadal hormones may not be comparable to initial
potentially organizing effects. Experts also highlighted
that accounting for the psychosocial aspects of the
transgender experience itself on development will re-
quire models that integrate both cognitive and psycho-
social functioning. The highest endorsed measurement
priorities were mental and behavioral health, execu-
tive function/cognitive control, and social awareness/
functioning. The importance of interrelations between
domains that mature during puberty/adolescence was
also emphasized, including bidirectional relationships
between cognitive and emotional control and links
between reward sensitivity and social value learning.
Regarding neuroimaging, experts stressed the impor-
tance of linking neural signatures to cognitive and be-
havioral measures, with attention to white matter
development. Notably, while there was consensus in
this approach to neuroimaging, there were divergent
views as to whether a neuroimaging protocol should
be prioritized in a study with limited resources. Some
experts noted that insufficient work has been done on
neural development during puberty in general and
expending resources on an expensive neuroimaging
protocol for this subset of youth may be premature,
while others felt that defining underlying brain mecha-
nisms by neuroimaging was important. Furthermore,
at the final review of the article, four co-authors
noted a concern with this specific Delphi consensus
recommendation: ‘‘Accounting for differences between
birth-assigned male youth versus birth-assigned female
youth is important, as sex is differentially related to the
rate and pattern of cognitive development, connectome
distinctiveness, and timing of peak brain volume.’’ The
four authors felt that instead of ‘‘peak brain volume,’’
a more appropriate measurement concept might be
that of ‘‘structural brain metrics’’ (e.g., thickness and
regional volumes).
Twelve different comparison groups were proposed
in the first round of the Delphi and 8 of the 12 groups
were rated as either first or second priority by at least 1
expert in the second Delphi round. This heterogeneity
underscores the complexity of selecting comparison
groups for this research and lends support to the ex-
perts’ recommendation to engage more than one com-
parison group. The highest rated comparison groups
were untreated transgender youth matched on pubertal
stage, cisgender youth matched on pubertal stage, and a
sample from a large-scale quasi-normative database
(e.g., from the ABCD study) used as a ‘‘brain growth
curve.’’ These comparison groups are not without weak-
nesses. Untreated transgender youth may differ in their
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intensity or experience of GD, level of parent support
(e.g., are the parents against GnRHa treatment?), and
socioeconomic status of the family and access to treat-
ment (e.g., insurance coverage). A cisgender compari-
son group would lack gender-minority experience
and associated stress.
Some statements approached, but did not reach con-
sensus. For example, many experts suggested continu-
ing assessments of transgender youth through young
adulthood (mid-20s) when prefrontal development
is near completion. Assessing adaptive functioning
(everyday skills) over time due to the bidirectional
link between executive functioning and adaptive be-
haviors was also often endorsed.
Not all relevant study considerations were raised by
the Delphi panel. Neurodevelopmental impacts of
pubertal suppression in transgender youth with neuro-
developmental differences/diagnoses (e.g., attention
deficit/hyperactivity disorder and autism spectrum dis-
order) were not specifically addressed by the experts.
Yet, evidence suggests an overoccurrence of neurodi-
versity characteristics (especially related to autism)
among gender-referred youth.55,63–66 The neurodeve-
lopmental impacts of pubertal suppression on neurodi-
verse gender-diverse youth might well be different
than in neurotypical gender-diverse youth, given vari-
ations in neurodevelopmental trajectories observed
across neurodevelopmental conditions.67–69
This study included experts from a range of relevant
disciplines—a strength and also a possible limitation.
The varied disciplines allowed for a broader range of
ideas and perspectives, but some specialized recom-
mendations might not have been sufficiently under-
stood by Delphi experts from other disciplines. It is
possible that some useful recommendations were lost
in the process because few experts had backgrounds
relevant to them. In fact, four recommendations were
dropped from consideration because more than nine
experts indicated they could not rate the item or skip-
ped the item. These four items included topics related
to advanced growth curve modeling, impact of GnRHa
on immune system functioning, multifactorial relation-
ships between GD and neurodevelopment, and challenges
associated with using alternative forms of measures in lon-
gitudinal designs. The Delphi team included experts across
the fields of neuroscience, neurodevelopment, develop-
mental measurement, and gender development; however,
most were not specialized in clinical transgender care
per se. This reflects the dearth of transgender care cli-
nicians/specialists with research productivity in ado-
lescent neurodevelopment. Thus, the experts could
comment with authority on neurodevelopment, in-
cluding gender development/dysphoria aspects of
study design, but the real-world clinical care consider-
ations may well be underdeveloped in the proposed
research design. For example, the everyday lived expe-
rience of transgender youth seeking gender-affirming
medical care would be unfamiliar to most neurodeve-
lopmental researchers. After the Delphi procedure
was completed, one panelist commented that pubertal
hormones might play a role in organizing neurodeve-
lopmental gender-related trajectories, including
identity itself, which would be important to consider
for a developmental study of gender diverse youth.
Despite these limitations, an international expert
team successfully completed an iterative Delphi proce-
dure achieving consensus around priority research de-
sign elements to study neurodevelopmental impacts
of pubertal suppression in transgender youth. The
resulting consensus parameter addresses broad design
issues, including comparison groups, longitudinal de-
sign, neurodevelopmental targets for assessment, and
measurement approaches. While it may not be possible
to incorporate all consensus methodologies into a sin-
gle study, this parameter may serve as a roadmap for
a range of research initiatives investigating pubertal
suppression treatment in transgender youth.
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